News

X-37, LLC Appoints David Gluckman, M.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that David Gluckman, M.D., has joined the company’s Board of Directors. Dr. Gluckman is Vice Chairman of Investment Banking and Global Head of Lazard’s Healthcare Group. He has been with Lazard since 1998, providing strategic and financial advice to senior executives ...

Read More...

X-37 Announces $14.5 Million Series A

SOUTH SAN FRANCISCO, November 14, 2019 -- X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that it has closed a $14.5 million Series A financing. The funding round was led by DCVC Bio and was joined by Alpha Intelligence Capital and Hemi Ventures. The Series A funding will be used to expand the number of drug development programs at X-37 and to advance identifi...

Read More...